Ketamine Interleaved With Electroconvulsive Therapy for Depression
Ketamine Interleaved With Electroconvulsive Therapy for Depression, A Pragmatic Randomised Controlled Pilot Trial
Lead SponsorTrinity College Dublin
Pragmatic, randomised, controlled, parallel group, pilot clinical trial of ketamine vs. midazolam interleaved with electroconvulsive therapy (ECT) as an adjunctive treatment for a major depressive episode. The main purpose of the pilot study is to assess trial processes to help inform a future definitive trial.
Patients referred for treatment with ECT at St Patrick's Mental Health Services for treatment of a depressive episode will be eligible for recruitment to the clinical trial. Participants will be invited to be randomised to a course of twice-weekly ketamine or midazolam infusions for the duration of ECT. Participants will receive the first allocated infusion following the first or second treatment with ECT. Block randomisation will be independently performed. Infusions will be delivered on separate days to ECT. Physical, psychotomimetic and cognitive outcomes will be monitored before, during and after infusions.Treatment-as-usual will continue throughout the entire trial.
Trial Interventions: participants will receive twice-weekly infusions of either ketamine at 0.5mg/Kg or midazolam at 0.045mg/Kg. All infusions will be administered by a Consultant Anaesthetist. Repeated infusions of allocated drug have been shown to be safe and well tolerated by patients with mental illness. Minor haemodynamic changes and psychotomimetic side effects can occur and will be assessed regularly during infusions and for 120 minutes afterwards. Participants will be followed-up at six weeks and three months after the final infusion to assess for relapse according to standardised criteria.
Participants will receive twice-weekly infusions of ketamine at 0.05mg/kg for the duration of treatment with ECT. All infusions will be administered by a Consultant Anaesthetist.
Participants will receive twice-weekly infusions of midazolam at 0.045mg/kg for the duration of treatment with ECT. All infusions will be administered by a Consultant Anaesthetist.
Inclusion Criteria: ≥18 years old Able to provide informed consent Voluntary admission for treatment of an acute depressive episode Meet DSM-V criteria for a major depressive disorder (MDD) and bipolar affective disorder (current episode depression) Montgomery Asberg Depression Rating Scale 10 item version (MADRS) score of ≥20 Referred for treatment with ECT Sufficiently physically healthy to receive ketamine/midazolam and ECT Exclusion Criteria: Inability to provide informed consent Current involuntary admission History of Axis 1 diagnosis other than major depression Medical condition rendering unfit for ECT Active suicidal intention Presence of major neurological or organic brain disorder Alcohol/substance dependence in previous six-months Pregnancy or inability to confirm use of adequate contraception during the trial Breastfeeding women Contraindications to ketamine Contraindications to midazolam